Press Releases Investors & News / Press Releases Year None20252024202320222021202020192018201720162015201420132012201120102009 01/12/25 Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 01/09/25 Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors 01/06/25 Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 Receive Email Alerts Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Submit. Required fields denoted by an asterisk (). Alert type Exelixis SEC Alert Exelixis End-of-Day SEC Alert Exelixis Calendar Alert Exelixis News Alert Exelixis Report Alert Email Leave this field blank Shareholder Tools Information Request Print Page RSS
Year None20252024202320222021202020192018201720162015201420132012201120102009 01/12/25 Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 01/09/25 Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors 01/06/25 Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
01/12/25 Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
01/09/25 Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
01/06/25 Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
